Начало・Списък с акции・Moderna Inc

Moderna Inc

Затворен

СекторЗдравеопазване

56.94 3.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

55.11

Максимум

58.19

Ключови измерители
By Trading Economics
Приходи	561M -782M
Продажби	-244M 145M
EPS	-1.97
Марж на печалбата	-539.31
Служители	4,700
EBITDA	554M -704M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-11.28% downside

Дивиденти
By Acuity
Следващи печалби	5.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-194M 22B
Предишно отваряне	53.62
Предишно затваряне	56.94

Настроения в новините

By Acuity

29%

71%

110 / 340 Класиране в Healthcare

Moderna Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2026 г., 20:07 ч. UTC

Social Media

News

Moderna initiates Phase 1 trial for mRNA-1469 vaccine, backed by CEPI's $50 million funding. Shares are higher despite earlier session pullback.

3.08.2026 г., 20:03 ч. UTC

News

Moderna Inc. shares are advancing as Citigroup raises its price target to $60 amid broader market strength and gains in major tech stocks.

31.07.2026 г., 23:26 ч. UTC

Moderna Inc. shares are lower in after-hours trading, continuing a decline from Friday's close without any specific news to explain the movement.

30.07.2026 г., 23:51 ч. UTC

Moderna Inc shares are higher in after-market trading, driven by a significant advance in the overall market, despite earlier fluctuations during the session.

29.07.2026 г., 23:51 ч. UTC

Moderna Inc is rising in after-market trading, aligning with broader market gains. The stock showed volatility earlier in the session without specific news driving the move.

28.07.2026 г., 18:36 ч. UTC

Moderna Inc shares are lower today, continuing a decline from Monday's close amid risk-off sentiment following significant declines in Asian markets.

27.07.2026 г., 19:07 ч. UTC

Social Media

Moderna Inc. is advancing as it initiates a Phase 1 trial for its mRNA-4200 cancer vaccine, with the first U.S. participant dosed on July 16, 2026.

24.07.2026 г., 19:03 ч. UTC

Social Media

News

Moderna Inc shares are lower today amid mixed options sentiment and increased demand for downside protection ahead of its upcoming earnings report.

23.07.2026 г., 19:56 ч. UTC

Social Media

News

Moderna Inc shares are lower, trading around $57.25, as options activity remains light. An mRNA vaccine is set for a Phase 1 trial in August.

21.07.2026 г., 20:07 ч. UTC

News

Social Media

Goldman Sachs raised Moderna's price target to $49.00 while maintaining a Neutral rating, reflecting a more favorable outlook on the company's valuation. Shares are higher today.

20.07.2026 г., 23:46 ч. UTC

Moderna Inc shares are lower in after-market hours amid rising Treasury yields and broader market trends, with no specific company news identified.

Сравнение с други в отрасъла

Ценова промяна

Moderna Inc Прогноза

Ценова цел

By TipRanks

-11.28% надолу

12-месечна прогноза

Среден 48.92 USD -11.28%

Висок 77 USD

Нисък 39 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Moderna Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на Moderna Inc през последните 3 месеца.

Настроение

By Acuity

110 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.